EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

BACKGROUND: Cutaneous adverse drug reactions (CADR) associated with oncology therapy involve 45–100% of patients receiving kinase inhibitors. Such adverse reactions may include skin inflammation, infection, pruritus and dryness, symptoms that can significantly affect the patient’s quality of life. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Joly-Tonetti, Nicolas, Ondet, Thomas, Monshouwer, Mario, Stamatas, Georgios N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786949/
https://www.ncbi.nlm.nih.gov/pubmed/33402117
http://dx.doi.org/10.1186/s12885-020-07685-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786949/
https://www.ncbi.nlm.nih.gov/pubmed/33402117
http://dx.doi.org/10.1186/s12885-020-07685-5

Ejemplares similares